Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-α and ribavirin therapy

S. Lee; M.W. Watson; J.P. Flexman; W. Cheng; T. Hammond; P. Price

doi:10.1002/jmv.21742

Back

Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-α and ribavirin therapy

Journal article

Peer reviewed

Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-α and ribavirin therapy

S. Lee, M.W. Watson, J.P. Flexman, W. Cheng, T. Hammond and P. Price

Journal of Medical Virology, Vol.82(4), pp.568-574

2010

DOI: https://doi.org/10.1002/jmv.21742

Files and links (1)

url

Link to Published Version *Subscription may be requiredView

Abstract

Natural killer (NK) cells are implicated in the regulation of a protective immune response in patients chronically infected with hepatitis C virus (HCV), but effects of interferon-alpha/ribavirin therapy on NK cell subsets and the consequences of viral clearance during therapy remain unclear. Samples were collected from chronically infected patients (n = 34) at baseline and from a subset after 3-10 months on pegylated interferon-alpha and ribavirin therapy (n = 19). NK cells present in cryopreserved PBMC were characterized by flow cytometry. Before therapy, the frequency of CD3-CD56+ NK cells was lower in patients than uninfected controls. Therapy increased proportions of CD56(bright) NK cells. Frequencies of CD56(dim) NK cells declined slightly while perforin and CD16 expression on CD56(dim) NK cells decreased compared to baseline samples. Evaluation of NK cell subsets at baseline did not identify patients able to achieve sustained virological response following therapy. However, therapy may promote the expansion of NK cells able to produce interferon-gamma, while minimizing cytotoxicity to limit liver damage.

Details

Title: Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-α and ribavirin therapy
Authors/Creators: S. Lee (Author/Creator) - Royal Perth Hospital
M.W. Watson (Author/Creator) - Royal Perth Hospital
J.P. Flexman (Author/Creator) - Royal Perth Hospital
W. Cheng (Author/Creator) - Royal Perth Hospital
T. Hammond (Author/Creator) - The University of Western Australia
P. Price (Author/Creator) - Royal Perth Hospital
Publication Details: Journal of Medical Virology, Vol.82(4), pp.568-574
Publisher: Wiley-Liss Inc
Identifiers: 991005542858607891
Copyright: © 2010 Wiley-Liss, Inc.
Murdoch Affiliation: Murdoch University
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

20 Record Views

17 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.6 Immunology; 1.6.1021 Natural Killer Cells
Web Of Science research areas: Virology
ESI research areas: Microbiology